Objective: Identify clinical features predictive of Lewy body pathology in Alzheimer's disease (AD) patients in an ongoing longitudinal clinicopathologic study.
| INTRODUC TI ON
Neurodegenerative disorders are complex diseases characterized by gradual clinical progression. Alzheimer's disease (AD) is the most common dementia and accounts for about 60% of cases;
1 the second most common is dementia with Lewy bodies (DLB). Cognitive decline is the most common symptom of all forms of dementia; however, AD and DLB share additional clinical and pathological features.
Indeed, neurofibrillary tangles and amyloid plaques are the typical pathologic findings of AD, whereas α-synuclein deposits forming
Lewy bodies (LB) and related neuritic pathology are the characteristic features of DLB. Given the clinical overlap, the definitive diagnosis of these disorders is still based on the pathology findings at autopsy, although certain clinical symptoms and features may improve the diagnostic accuracy during a patient's lifetime. While clinical diagnosis of DLB has relatively high specificity (>80%), the sensitivity is low (20%-40%). 2 In addition, autopsy studies have shown coexisting AD pathology in most DLB cases, and up to 60% of
AD cases have Lewy-type synucleinopathy (LTS) pathology (AD with
LBs that do not meet DLB pathological criteria). 3, 4 Neuroimaging and electrophysiological tests may help differentiate between the different disorders but these tests are often not widely accessible to all the medical professionals involved in the care of these patients. 5, 6 We report the findings of an autopsy series of dementia cases with neuropathologically confirmed AD. We identified a number of clinical features that may predict the presence of co-occurring LTS in the post-mortem pathological examination. Our study will further elucidate the role of specific motor and non-motor findings in the diagnosis of the LTS deposition and the clinical features of AD cases with mixed pathology that do not meet the criteria for DLB.
| MATERIAL AND ME THODS

| Case ascertainment
We queried the database of the 
| Clinical assessment
Each participant received research-dedicated annual physical, neurological and cognitive examinations by movement disorder and behavioral neurology specialists. Further details have been described previously. 8, 11, 12 All subjects underwent a standardized neuropsy- 
| Neuropathology assessment
All subjects underwent autopsy and a standardized neuropathological assessment; details regarding neuropathological collection are reported elsewhere. 7, 8 All cases had neuritic plaque density ratings performed according to the Consortium to Establish a Registry for Alzheimer Disease (CERAD) criteria for the diagnosis of AD, 13 and all cases were assigned a Braak neurofibrillary stage and were rated according to National Institute on Aging (NIA)-Reagan criteria. 9, 10 In addition, Apo E genotyping was performed in each subject enrolled.
Subjects received a clinicopathological diagnosis of AD if they had a clinical history of dementia and were classified as "intermediate" or "high" according to the NIA-Reagan criteria. 10 PDD was differentiated from DLB according to the third DLB consortium criteria;
Conclusions: Our study suggests that the presence (or absence) of LTS influences motor and non-motor clinical findings in AD patients. These findings may lead to biomarkers that allow for more targeted treatment of AD.
K E Y W O R D S
Alzheimer's disease, Lewy bodies, neuropsychology, pathology PDD was diagnosed if diagnostic criteria for PD were met, 14 and
Parkinsonism began at least 1 year before diagnosis of dementia.
Otherwise, if distribution of LTS met "intermediate" or "high" criteria, then the diagnosis of DLB was assigned. 15 Subjects with LTS histopathology were classified according to the Unified Staging System for Lewy Body Disorders 16 after immunohistochemical detection of phosphorylated α-synuclein on 5 μm paraffin sections pretreated with proteinase K.
11
The cases were divided into four diagnostic groups according to their clinical features plus AD and LTS histopathology: 16 DLB/AD, PDD/AD, ADLB and AD only. ADLB cases were cases that met the pathologic criteria for AD and had LTS pathology present that was insufficient to meet clinical or pathological criteria for either PD or DLB. 8 Cases with LTS that met the diagnostic criteria for DLB or PDD without AD were excluded from our study.
Tissue-processing methods have been previously described. 7, 8 Briefly, the cerebrum was cut in the coronal plane at the time of brain removal into 1-cm-thick slices and then divided into left and right halves. The slices from the right half were frozen between slabs of dry ice while the slices from the left half were fixed by immersion in neutral-buffered 4% formaldehyde for 48 hours at 4°C.
Formaldehyde-fixed paraffin-embedded sections were stained with haematoxylin and eosin, while large-format, 40-to 80-μm-thick formaldehyde-fixed sections were stained for plaques, tangles and other features using Gallyas, Thioflavin-S and Campbell-Switzer methods. 17 Thioflavin-S is one of two methods recommended and validated for neuritic plaque density grading by CERAD. 13, 18 The
Braak neurofibrillary tangle (NFT) staging followed the original protocol and was originally described using the Gallyas stain 19 on similarly thick sections. The Campbell-Switzer silver stain is that used by Thal to establish amyloid staging. 
| Statistical analysis
Mean levels were compared among groups using one-way analysis of variance, and proportions were compared among groups using the Pearson chi-square test. Pairwise comparisons of adjusted means were made using a general linear model with terms for group, age, sex and e4 carrier status.
| RE SULTS
We identified 584 cases with a final clinicopathological diagnosis; among these there were 32 cases of DLB/AD, 54 ADLB, 41 PDD/ AD and 70 AD only. The mean activity of daily living as well as mean motor scores (UPDRS parts II and III) was higher in subjects with LTS (Table 1) .
Multiple neuropsychological tests (COWAT, HAM-D, BNT, AVLT Total Learning and Trail-making test A) as well as HAM-D correlated
significantly with LTS pathology.
| Alzheimer's disease comparison to ADLB
Hoehn and Yahr staging was higher in the ADLB group. On the cognitive tests, AVLT total learning (P = 0.02) and BNT (P = 0.05) were worse in ADLB compared to AD alone.
| DLB/AD comparison to ADLB
When we performed an additional analysis comparing DLB/AD cases with ADLB, the adjusted mean total scores of Hoehn and Yahr Scale (Δ:
1.39, 95%CI: 0.64-2.14; P = <0.001) and UPDRS III were significantly different (Δ: 17, 95%CI: 8-26, P = <0.001). Rigidity (P = <0.001) and bradykinesia (P = 0.003) were still significantly different, whereas tremor was not were not statistically different. Notably, there was no difference in the presence of Apo E4 between groups with 40%-50% occurrence (Table 1) .
| D ISCUSS I ON
This study found that a number of clinical symptoms and neuropsychological features are correlated with the presence of postmortem LTS pathology among patients with pathologically confirmed AD.
In particular, the overall score of UPDRS II and III and a number of Indeed, mixed pathology is associated with faster cognitive decline in subjects with mild cognitive impairment or dementia, and shorter survival times [22] [23] [24] Thus, subjects with concurrent LB pathology in the treatment arm of a trial may reduce the chance of showing a clinically meaningful benefit. Furthermore, the relationship between LBs and amyloid is still unclear, and it is unknown whether LBs might confer resistance to anti-amyloid therapies.
Our study has a number of strengths. We performed comprehensive clinical and neuropathological assessments in a standardized manner. Our study is based on a large neuropathological series;
in addition, most of our subjects have volunteered from the community rather than being collected at a tertiary care centre. On the other hand, our case distribution was limited by being predominantly very elderly, well-educated, middle-and upper-income individuals originally from the Midwest or the northeastern United States residing in Maricopa County, Arizona. Case composition may also be affected by volunteer bias, and subjects may be more aware of neurodegeneration because of incipient disease or because of personal and familial awareness.
This study identified clinical differences in AD with and without concomitant LTS, even in subjects whose LB pathology did not meet criteria for DLB. In particular, higher UPDRS parts II and III scores and impairment of the executive and visual functions on cognitive testing was significantly correlated to the presence of LTS in the brains of individuals with dementia but who did not meet criteria for DLB. Future studies are needed to confirm and expand these findings in order to predict the presence of LTS in subjects with AD.
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